Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT05428007 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT05428007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05428007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Recruiting
Start date
February 2, 2023
Completion date
February 29, 2028
Enrollment
105 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, unresectable melanoma